Please assess the completion status of the following clinical trial:

Trial Title: Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~Cohort A (patients switched from VKA to Pradaxa)~* Written informed consent prior to participation.~* Female or male patients ≥ 20 years of age with a diagnosis of non-valvular atrial fibrillation (NVAF).~* At least 3 months of continuous VKA treatment for stroke prevention prior to baseline assessment.~* Patients switched to Pradaxa prior to baseline assessment according to the physician's discretion and the Summary of Product Characteristics (SmPCs)/reimbursement criteria.~OR Cohort B (patients newly initiated Pradaxa or VKA)~* Written informed consent prior to participation.~* Female or male patients ≥ 20 years of age, newly diagnosed with NVAF, and no previous treatment for stroke prevention (no use of any OAC within 1 year prior to enrolment).~* Patients initiated stroke prevention treatment with Pradaxa or VKA according to the physician's discretion and the SmPCs/reimbursement criteria.~Exclusion criteria:~* Contraindication to the use of Pradaxa® or VKA as described in the SmPCs.~* Patients receiving Pradaxa® or VKA for any other condition than stroke prevention in NVAF.~* Current participation in any clinical trial of a drug or device.~* Current participation in an AF-related registry, e.g. the Gloria AF program.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: None): consented patients with NVAF in Taiwan with a previous VKA therapy, followed by switching to Pradaxa®
- Cohort B (Type: None): patients being newly diagnosed with NVAF and initiated on Pradaxa®

Based on this trial design, predict the completion outcome and termination type (if applicable).